PMID- 36017860
OWN - NLM
STAT- MEDLINE
DCOM- 20221104
LR  - 20221104
IS  - 1875-5550 (Electronic)
IS  - 1389-2037 (Linking)
VI  - 23
IP  - 8
DP  - 2022
TI  - T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by 
      Mediating NRF2 Expression.
PG  - 563-570
LID - 10.2174/1389203723666220823152239 [doi]
AB  - BACKGROUND: The roles of T-Box transcription factor (TBX2) in endometrial cancer 
      are still not clear. This study was designed to explore the roles of TBX2 in 
      endometrial cancer and the underlying mechanisms. METHODS: The knockdown and 
      overexpression of TBX2 in endometrial cancer cell lines were constructed by using 
      lentivirus transduction. The xenograft animal model was established by using 
      stable endometrial cancer cell lines. Cell viability was determined by the CCK-8 
      assay. The mRNA and protein levels of target genes were determined by using qPCR 
      and Western blotting, respectively. ChIP assay was used to determine the 
      interactions between TBX2 and nuclear factor erythroid 2-related factor 2 (NRF2). 
      RESULTS: The upregulation of TBX2 was observed in endometrial cancer tissues from 
      patients with Cisplatin- resistance and Cisplatin-resistant cells. Interestingly, 
      TBX2 regulated cell viability and Cisplatin resistance of endometrial cancer 
      cells. In addition, the regulatory effects of TBX2 on chemo-resistance of 
      endometrial cancer cells were associated with the NRF2 signaling pathways. 
      Consistently, the endometrial cancer xenograft animal model revealed that TBX2 
      regulated tumor growth and Cisplatin resistance, and its regulatory effects were 
      in part by the regulation of NRF2 signaling pathways. CONCLUSION: TBX 2 enhanced 
      Cisplatin resistance of endometrial cancer by regulating the NRF2 signaling 
      pathways.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Ding, Ning
AU  - Ding N
AD  - Department of Gynaecology, Zibo Central Hospital, No. 54 Gongqingtuan Road, 
      Zhangdian District, Zibo 255036, Shandong, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Department of Gynaecology, Zibo Central Hospital, No. 54 Gongqingtuan Road, 
      Zhangdian District, Zibo 255036, Shandong, China.
FAU - Yu, Xiaohui
AU  - Yu X
AD  - Department of Gynaecology, Zibo Central Hospital, No. 54 Gongqingtuan Road, 
      Zhangdian District, Zibo 255036, Shandong, China.
FAU - Zhuang, Shichao
AU  - Zhuang S
AD  - Department of Gynaecology, Zibo Central Hospital, No. 54 Gongqingtuan Road, 
      Zhangdian District, Zibo 255036, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Protein Pept Sci
JT  - Current protein & peptide science
JID - 100960529
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (T-Box Domain Protein 2)
RN  - 0 (T-Box Domain Proteins)
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - *Antineoplastic Agents/pharmacology
MH  - Cell Line, Tumor
MH  - Cisplatin/pharmacology
MH  - Drug Resistance, Neoplasm
MH  - *Endometrial Neoplasms/genetics/metabolism
MH  - NF-E2-Related Factor 2/genetics/metabolism/pharmacology
MH  - *T-Box Domain Proteins/genetics
OTO - NOTNLM
OT  - Endometrial cancer
OT  - NRF2
OT  - TBX2
OT  - chemo-resistance
OT  - cisplatin resistance
OT  - mRNA
EDAT- 2022/08/27 06:00
MHDA- 2022/11/04 06:00
CRDT- 2022/08/26 06:43
PHST- 2022/03/20 00:00 [received]
PHST- 2022/06/17 00:00 [revised]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/11/04 06:00 [medline]
PHST- 2022/08/26 06:43 [entrez]
AID - CPPS-EPUB-125813 [pii]
AID - 10.2174/1389203723666220823152239 [doi]
PST - ppublish
SO  - Curr Protein Pept Sci. 2022;23(8):563-570. doi: 
      10.2174/1389203723666220823152239.